All News

ACR Best

#ACR 2024 BEST Abstracts from Day 2

d Jack Cush, MD

Here’s a collection of some of the best abstracts presented on day 2 of ACR 2024 as selected by the RheumNow faculty.

 

Read Article
Conv3.jpg

ACR 2024 - Day 2 Report

d Jack Cush, MD

Plenary sessions began the day, followed by thousands on the abstract floor. Here are a few of my favorite presentations from day 2 at ACR 2024.

Read Article
bathroom scale

Shedding Weight and Pain: The Promise of Anti-Obesity Medications in RA

d Caoilfhionn Marie Connolly, MD

With the advent of FDA-approved anti-obesity medications such as semaglutide and tirzepatide, a new avenue for managing this challenging patient population has emerged. But how might these drugs impact the trajectory of RA, and are we on the cusp of a paradigm shift?

Read Article
Dentition is important in RA, but it's easy to forget it's a matter of life or death. NHANES data shows fewer teeth strongly correlates with higher mortality (esp cardiovascular). Missing teeth = CV death HR >30 Holistic dentition is holistic RA care #ACR24 ABST1325 @RheumNow https://t.co/Z40bSFybuS

Links:

David Liew drdavidliew ( View Tweet)
Rheumatic irAEs can get on the CAR-T bandwagon, too! CAR-T can invoke new rheumatological issues (not just cytokine release) - see @DrGomezPuerta's experience. Infrequent, but if CAR-T in general becomes common, yet another job for us to attend to... #ACR24 ABST2004 @RheumNow https://t.co/xBSlhUdkNr

Links:

David Liew drdavidliew ( View Tweet)
Now that nipocalimab is approved for Sjogren's Disease, what about vaccination response whilst on this FcRn inhibitor (inherently lowers IgG)? Actually, not bad: takes a little longer to get there, but reassuring! (always fun to get to know a new med) #ACR24 ABST1988 @RheumNow https://t.co/IYqIGo5xVP

Links:

David Liew drdavidliew ( View Tweet)
Active early RA accentuates regional MSK pain. Non-articular pain: easy to ignore & focus on active RA yes, some is related to RA dx activity BUT actually it becomes a bigger issue over time Worth identifying to: clarify what isn't RA Rx appropriately #ACR24 ABST1335 @RheumNow https://t.co/iN5rsyr7Bx

Links:

David Liew drdavidliew ( View Tweet)
Here's a meta-analysis of MACE/malignancy in JAKi vs TNFi in observational cohort studies. All the epidemiological challenges here aside, it's a good reminder that with ORAL Surveillance it's *cardiovascular risk enriched pts* we're concerned about. #ACR24 ABST2264 @RheumNow https://t.co/vIXlrI3V2d

Links:

David Liew drdavidliew ( View Tweet)
Post hoc analysis of SPIRIT H2H evaluated nail involvement as a measure of ttnt response in PsA. -Pts with nail involvement treated with IXE or ADA had higher SJC and TJC improvement vs those without involvement at W12, W24 and W52. -IXE achieved rapid response for DAPSA-LDA as… https://t.co/SR36qCthQo https://t.co/hI3tD5hATJ

Links:

Adela Castro AdelaCastro222 ( View Tweet)
3D management of Sscl from @delgaldoFrances -Time -Severity -Type of organ involvement *Identify phenotypes: fibrotic vs vascular damage. *Raynaud’s red flags: +ANA, puffy fingers, abn capillaroscopy. *Early ttnt of of digital ulcers delays onset of PAH. *High IFN-I =marker of… https://t.co/ByfuV0MJds https://t.co/GdRVwuRf4E

Links:

Adela Castro AdelaCastro222 ( View Tweet)
My ramblings on the SELECT-GCA study and predictions of the place of upadacitinib in clinical practice in GCA are up now on RheumNow #ACR24 @RheumNow https://t.co/DR5VgVmdse

Links:

Richard Conway RichardPAConway ( View Tweet)

I've shared some further thoughts on @jeffsparks SAIL-RA study and its finding of the strong association of RA-ILD with disease activity in early RA. And of course couldn't resist going on a tangent about the ACR ILD guidelines! #ACR24 @RheumNow https://t.co/UUDbWw38Im

Links:

Richard Conway RichardPAConway ( View Tweet)

A key practice changing study (I hope) from #ACR24 has been the preCARA study. Fertility increases with aggressive disease control. My video on this study is up now on @RheumNow https://t.co/Pf3rdTHbOJ

Links:

Richard Conway RichardPAConway ( View Tweet)

The TAPIR study presented at #ACR24 may not be as attention grabbing as others like SELECT-GCA, but in my opinion it is arguablyone of the most important ANCA-vasculitis studies ever. I've shared some further thoughs in an article on @RheumNow https://t.co/mImAE8ezSQ

Links:

Richard Conway RichardPAConway ( View Tweet)

RheumNow Day 2 Recap: ACR Convergence 2024 Highlights https://t.co/YAwOEaNsWs

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty

Dr. John Cush RheumNow ( View Tweet)

We saw evidence for JAK use in GCA this conference... what about IL-1 inhibition? Double-blind RCT: Anakinra vs. PBO w/ similar GC taper in GCA pt NO difference in relapse rate at 26, 52 wks despite addition of Anakinra @RheumNow #ACR24 Abst1699 https://t.co/gUb0gGJjTG

Links:

Brian Jaros, MD Dr_Brian_MD ( View Tweet)

VERY exciting SLE update from Fava et al. Machine learning used to generate urinary protein panel predictive of intra-renal inflammation BETTER than serum biomarkers C3, C4, dsDNA Also monitoring tool for renal response. Outstanding. @RheumNow #ACRbest #ACR24 https://t.co/YXgKrSU4UQ

Links:

Brian Jaros, MD Dr_Brian_MD ( View Tweet)
To stop tsDMARD / bDMARD To improve #COVIDVACCINE response in those w several previous #COVID19 #vaccinations is NOT necessary This will change my practice! #ACR24 @RheumNow @ACRheum https://t.co/WXeqMOEfuA

Links:

Janet Pope Janetbirdope ( View Tweet)

What a result!!! Crowed split 49% against and 51% for MCTD as a unique disease entity Given pre-debate poll of >70% for MCTD, looks like an overall win for the “NOT” group Fantastic session from all the presenters @RheumNow #ACR24 https://t.co/GgTVQ1VNWP

Links:

Brian Jaros, MD Dr_Brian_MD ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×